Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection

The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Flor, Noelia, García, María Inés, Molineri, Ana Ines, Botasso, Oscar, Diez, Cristina, Veaute, Carolina
Formato: Artículo
Lenguaje:Inglés
Publicado: Elsevier 2023
Materias:
Acceso en línea:http://hdl.handle.net/20.500.12123/16258
https://www.sciencedirect.com/science/article/abs/pii/S0264410X23012215
https://doi.org/10.1016/j.vaccine.2023.10.038
_version_ 1855485728833667072
author Flor, Noelia
García, María Inés
Molineri, Ana Ines
Botasso, Oscar
Diez, Cristina
Veaute, Carolina
author_browse Botasso, Oscar
Diez, Cristina
Flor, Noelia
García, María Inés
Molineri, Ana Ines
Veaute, Carolina
author_facet Flor, Noelia
García, María Inés
Molineri, Ana Ines
Botasso, Oscar
Diez, Cristina
Veaute, Carolina
author_sort Flor, Noelia
collection INTA Digital
description The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG.
format Artículo
id INTA16258
institution Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina)
language Inglés
publishDate 2023
publishDateRange 2023
publishDateSort 2023
publisher Elsevier
publisherStr Elsevier
record_format dspace
spelling INTA162582023-12-18T13:26:01Z Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection Flor, Noelia García, María Inés Molineri, Ana Ines Botasso, Oscar Diez, Cristina Veaute, Carolina Vacuna Inmunidad COVID-19 Coronavirus del síndrome respiratorio agudo grave 2 Vaccines Immunity Severe acute respiratory syndrome coronavirus 2 Serovigilancia SARS-CoV2 Serosurveillance The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG. EEA Rafaela Fil: Flor, Noelia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina Fil: García, María Ines. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina Fil: Molineri, Ana Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina Fil: Molineri, Ana Ines. Consejo Nacional de Ciencia y Tecnología (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina Fil: Molineri, Ana Ines. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina Fil: Botasso, Oscar. Universidad Nacional de Rosario; Argentina Fil: Botasso, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Inmunología clínica y Experimental de Rosario (IDICER); Argentina Fil: Diez, Cristina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina Fil: Veaute; Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina Fil: Veaute, Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina 2023-12-15T17:58:19Z 2023-12-15T17:58:19Z 2023-10 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/16258 https://www.sciencedirect.com/science/article/abs/pii/S0264410X23012215 1873-2518 0264-410X https://doi.org/10.1016/j.vaccine.2023.10.038 eng info:eu-repo/semantics/restrictedAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf Elsevier Vaccine 41 (48) : 7206-7211 (2023)
spellingShingle Vacuna
Inmunidad
COVID-19
Coronavirus del síndrome respiratorio agudo grave 2
Vaccines
Immunity
Severe acute respiratory syndrome coronavirus 2
Serovigilancia
SARS-CoV2
Serosurveillance
Flor, Noelia
García, María Inés
Molineri, Ana Ines
Botasso, Oscar
Diez, Cristina
Veaute, Carolina
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title_full Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title_fullStr Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title_full_unstemmed Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title_short Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title_sort antibodies to sars cov2 induced by vaccination and infection correlate with protection against the infection
topic Vacuna
Inmunidad
COVID-19
Coronavirus del síndrome respiratorio agudo grave 2
Vaccines
Immunity
Severe acute respiratory syndrome coronavirus 2
Serovigilancia
SARS-CoV2
Serosurveillance
url http://hdl.handle.net/20.500.12123/16258
https://www.sciencedirect.com/science/article/abs/pii/S0264410X23012215
https://doi.org/10.1016/j.vaccine.2023.10.038
work_keys_str_mv AT flornoelia antibodiestosarscov2inducedbyvaccinationandinfectioncorrelatewithprotectionagainsttheinfection
AT garciamariaines antibodiestosarscov2inducedbyvaccinationandinfectioncorrelatewithprotectionagainsttheinfection
AT molinerianaines antibodiestosarscov2inducedbyvaccinationandinfectioncorrelatewithprotectionagainsttheinfection
AT botassooscar antibodiestosarscov2inducedbyvaccinationandinfectioncorrelatewithprotectionagainsttheinfection
AT diezcristina antibodiestosarscov2inducedbyvaccinationandinfectioncorrelatewithprotectionagainsttheinfection
AT veautecarolina antibodiestosarscov2inducedbyvaccinationandinfectioncorrelatewithprotectionagainsttheinfection